Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism

Background Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurological sciences 2024-07, Vol.45 (7), p.3509-3511
Hauptverfasser: Di Rauso, Giulia, Orlandi, Niccolò, Jacopetti, Marco, Bigliardi, Guido, Antonelli, Francesca, Meletti, Stefano, Rispoli, Vittorio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3511
container_issue 7
container_start_page 3509
container_title Neurological sciences
container_volume 45
creator Di Rauso, Giulia
Orlandi, Niccolò
Jacopetti, Marco
Bigliardi, Guido
Antonelli, Francesca
Meletti, Stefano
Rispoli, Vittorio
description Background Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomatic treatments are required. Typical and atypical neuroleptics as well as tetrabenazine are considered therapies of choice. However, anecdotal reports of antiseizures medications and botulinum neurotoxin injection effectiveness have been described. Methods We described a case of severely disabling acute-onset lesional HB/HC, where high dosage of first- and second-line therapies was contraindicated due to patient’s comorbidities. Results After botulin neurotoxin (BoNT) injections in his left upper limb muscles (biceps brachii, triceps brachii, teres major, and deltoid), the patient experienced gradual reduction of hyperkinetic movements. The gradual discontinuation of topiramate (TPM) did not worsen the clinical picture. Discussion The reduction of hyperkinetic movements led to rhabdomyolysis resolution as well as cutaneous injuries healing with renal function improvement, so that the patient was able to be eligible for rehabilitation, which was prevented by HB/HC itself. The clinical improvement was consistent with BoNT pharmacokinetic. The administration of BoNT early after the onset of lesional HB/HC remarkably modified the clinical management and drove toward comorbidities resolution and rehabilitation. Conclusion The present case highlights the effectiveness of unconventional therapeutic options in disabling acute onset lesional HB/HC when first-line therapies are contraindicated. Particularly, this report may encourage BoNT application in the early stage of movement disorder emergencies.
doi_str_mv 10.1007/s10072-024-07465-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3022567154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3067592768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-66c27a253ec07a0fbf619f2ee770d0b11e34329f0f4104bcc4810ccf282612f53</originalsourceid><addsrcrecordid>eNp9kMtKxTAQhoMoHm8v4EIKbtxUJ5cm7VLFGwpudB3SONEe0kaTFPTt7fEcFVy4yYTMN_-Ej5B9CscUQJ2kxclKYKIEJWRVwhrZolUDJReqXl_daa3EjGynNAcAKijfJDNeV6KuG7FFbs9CHn03jH0x4BhDDu_dUJhUoIn-o8gRTe5xyMXi1Y4ZyzAkzIXH1IXB-OIF-6413nep3yUbzviEe6u6Qx4vLx7Or8u7-6ub89O70nImcymlZcqwiqMFZcC1TtLGMUSl4AlaSpELzhoHTlAQrbWipmCtYzWTlLmK75CjZe5rDG8jpqz7Lln03gwYxqQ5MFZJRSsxoYd_0HkY4_TvBSVV1TAl64liS8rGkFJEp19j15v4oSnohWS9VK0n1fpLtYZp6GAVPbY9Pv2MfLudAL4E0tQanjH-7v4n9hPHy4jl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067592768</pqid></control><display><type>article</type><title>Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Di Rauso, Giulia ; Orlandi, Niccolò ; Jacopetti, Marco ; Bigliardi, Guido ; Antonelli, Francesca ; Meletti, Stefano ; Rispoli, Vittorio</creator><creatorcontrib>Di Rauso, Giulia ; Orlandi, Niccolò ; Jacopetti, Marco ; Bigliardi, Guido ; Antonelli, Francesca ; Meletti, Stefano ; Rispoli, Vittorio</creatorcontrib><description>Background Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomatic treatments are required. Typical and atypical neuroleptics as well as tetrabenazine are considered therapies of choice. However, anecdotal reports of antiseizures medications and botulinum neurotoxin injection effectiveness have been described. Methods We described a case of severely disabling acute-onset lesional HB/HC, where high dosage of first- and second-line therapies was contraindicated due to patient’s comorbidities. Results After botulin neurotoxin (BoNT) injections in his left upper limb muscles (biceps brachii, triceps brachii, teres major, and deltoid), the patient experienced gradual reduction of hyperkinetic movements. The gradual discontinuation of topiramate (TPM) did not worsen the clinical picture. Discussion The reduction of hyperkinetic movements led to rhabdomyolysis resolution as well as cutaneous injuries healing with renal function improvement, so that the patient was able to be eligible for rehabilitation, which was prevented by HB/HC itself. The clinical improvement was consistent with BoNT pharmacokinetic. The administration of BoNT early after the onset of lesional HB/HC remarkably modified the clinical management and drove toward comorbidities resolution and rehabilitation. Conclusion The present case highlights the effectiveness of unconventional therapeutic options in disabling acute onset lesional HB/HC when first-line therapies are contraindicated. Particularly, this report may encourage BoNT application in the early stage of movement disorder emergencies.</description><identifier>ISSN: 1590-1874</identifier><identifier>ISSN: 1590-3478</identifier><identifier>EISSN: 1590-3478</identifier><identifier>DOI: 10.1007/s10072-024-07465-0</identifier><identifier>PMID: 38548894</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antipsychotics ; Botulinum toxin ; Botulinum Toxins, Type A - administration &amp; dosage ; Botulinum Toxins, Type A - therapeutic use ; Brief Communication ; Cerebrovascular diseases ; Chorea - drug therapy ; Comorbidity ; Contraindications ; Dyskinesias - drug therapy ; Dyskinesias - etiology ; Humans ; Male ; Medical treatment ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Movement disorders ; Muscles ; Neurology ; Neuromuscular Agents - administration &amp; dosage ; Neuromuscular Agents - therapeutic use ; Neuroradiology ; Neurosurgery ; Patients ; Pharmacokinetics ; Psychiatry ; Quality of life ; Rehabilitation ; Renal function ; Rhabdomyolysis ; Tetrabenazine ; Topiramate ; Vascular diseases ; Wound healing</subject><ispartof>Neurological sciences, 2024-07, Vol.45 (7), p.3509-3511</ispartof><rights>Fondazione Società Italiana di Neurologia 2024</rights><rights>2024. Fondazione Società Italiana di Neurologia.</rights><rights>Fondazione Società Italiana di Neurologia 2024.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-66c27a253ec07a0fbf619f2ee770d0b11e34329f0f4104bcc4810ccf282612f53</cites><orcidid>0000-0001-6728-8481 ; 0000-0003-0334-539X ; 0000-0001-5312-7206 ; 0000-0001-7159-9311 ; 0000-0002-5717-7363</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10072-024-07465-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10072-024-07465-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38548894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Rauso, Giulia</creatorcontrib><creatorcontrib>Orlandi, Niccolò</creatorcontrib><creatorcontrib>Jacopetti, Marco</creatorcontrib><creatorcontrib>Bigliardi, Guido</creatorcontrib><creatorcontrib>Antonelli, Francesca</creatorcontrib><creatorcontrib>Meletti, Stefano</creatorcontrib><creatorcontrib>Rispoli, Vittorio</creatorcontrib><title>Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism</title><title>Neurological sciences</title><addtitle>Neurol Sci</addtitle><addtitle>Neurol Sci</addtitle><description>Background Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomatic treatments are required. Typical and atypical neuroleptics as well as tetrabenazine are considered therapies of choice. However, anecdotal reports of antiseizures medications and botulinum neurotoxin injection effectiveness have been described. Methods We described a case of severely disabling acute-onset lesional HB/HC, where high dosage of first- and second-line therapies was contraindicated due to patient’s comorbidities. Results After botulin neurotoxin (BoNT) injections in his left upper limb muscles (biceps brachii, triceps brachii, teres major, and deltoid), the patient experienced gradual reduction of hyperkinetic movements. The gradual discontinuation of topiramate (TPM) did not worsen the clinical picture. Discussion The reduction of hyperkinetic movements led to rhabdomyolysis resolution as well as cutaneous injuries healing with renal function improvement, so that the patient was able to be eligible for rehabilitation, which was prevented by HB/HC itself. The clinical improvement was consistent with BoNT pharmacokinetic. The administration of BoNT early after the onset of lesional HB/HC remarkably modified the clinical management and drove toward comorbidities resolution and rehabilitation. Conclusion The present case highlights the effectiveness of unconventional therapeutic options in disabling acute onset lesional HB/HC when first-line therapies are contraindicated. Particularly, this report may encourage BoNT application in the early stage of movement disorder emergencies.</description><subject>Antipsychotics</subject><subject>Botulinum toxin</subject><subject>Botulinum Toxins, Type A - administration &amp; dosage</subject><subject>Botulinum Toxins, Type A - therapeutic use</subject><subject>Brief Communication</subject><subject>Cerebrovascular diseases</subject><subject>Chorea - drug therapy</subject><subject>Comorbidity</subject><subject>Contraindications</subject><subject>Dyskinesias - drug therapy</subject><subject>Dyskinesias - etiology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Movement disorders</subject><subject>Muscles</subject><subject>Neurology</subject><subject>Neuromuscular Agents - administration &amp; dosage</subject><subject>Neuromuscular Agents - therapeutic use</subject><subject>Neuroradiology</subject><subject>Neurosurgery</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Psychiatry</subject><subject>Quality of life</subject><subject>Rehabilitation</subject><subject>Renal function</subject><subject>Rhabdomyolysis</subject><subject>Tetrabenazine</subject><subject>Topiramate</subject><subject>Vascular diseases</subject><subject>Wound healing</subject><issn>1590-1874</issn><issn>1590-3478</issn><issn>1590-3478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxTAQhoMoHm8v4EIKbtxUJ5cm7VLFGwpudB3SONEe0kaTFPTt7fEcFVy4yYTMN_-Ej5B9CscUQJ2kxclKYKIEJWRVwhrZolUDJReqXl_daa3EjGynNAcAKijfJDNeV6KuG7FFbs9CHn03jH0x4BhDDu_dUJhUoIn-o8gRTe5xyMXi1Y4ZyzAkzIXH1IXB-OIF-6413nep3yUbzviEe6u6Qx4vLx7Or8u7-6ub89O70nImcymlZcqwiqMFZcC1TtLGMUSl4AlaSpELzhoHTlAQrbWipmCtYzWTlLmK75CjZe5rDG8jpqz7Lln03gwYxqQ5MFZJRSsxoYd_0HkY4_TvBSVV1TAl64liS8rGkFJEp19j15v4oSnohWS9VK0n1fpLtYZp6GAVPbY9Pv2MfLudAL4E0tQanjH-7v4n9hPHy4jl</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Di Rauso, Giulia</creator><creator>Orlandi, Niccolò</creator><creator>Jacopetti, Marco</creator><creator>Bigliardi, Guido</creator><creator>Antonelli, Francesca</creator><creator>Meletti, Stefano</creator><creator>Rispoli, Vittorio</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6728-8481</orcidid><orcidid>https://orcid.org/0000-0003-0334-539X</orcidid><orcidid>https://orcid.org/0000-0001-5312-7206</orcidid><orcidid>https://orcid.org/0000-0001-7159-9311</orcidid><orcidid>https://orcid.org/0000-0002-5717-7363</orcidid></search><sort><creationdate>20240701</creationdate><title>Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism</title><author>Di Rauso, Giulia ; Orlandi, Niccolò ; Jacopetti, Marco ; Bigliardi, Guido ; Antonelli, Francesca ; Meletti, Stefano ; Rispoli, Vittorio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-66c27a253ec07a0fbf619f2ee770d0b11e34329f0f4104bcc4810ccf282612f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antipsychotics</topic><topic>Botulinum toxin</topic><topic>Botulinum Toxins, Type A - administration &amp; dosage</topic><topic>Botulinum Toxins, Type A - therapeutic use</topic><topic>Brief Communication</topic><topic>Cerebrovascular diseases</topic><topic>Chorea - drug therapy</topic><topic>Comorbidity</topic><topic>Contraindications</topic><topic>Dyskinesias - drug therapy</topic><topic>Dyskinesias - etiology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Movement disorders</topic><topic>Muscles</topic><topic>Neurology</topic><topic>Neuromuscular Agents - administration &amp; dosage</topic><topic>Neuromuscular Agents - therapeutic use</topic><topic>Neuroradiology</topic><topic>Neurosurgery</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Psychiatry</topic><topic>Quality of life</topic><topic>Rehabilitation</topic><topic>Renal function</topic><topic>Rhabdomyolysis</topic><topic>Tetrabenazine</topic><topic>Topiramate</topic><topic>Vascular diseases</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Rauso, Giulia</creatorcontrib><creatorcontrib>Orlandi, Niccolò</creatorcontrib><creatorcontrib>Jacopetti, Marco</creatorcontrib><creatorcontrib>Bigliardi, Guido</creatorcontrib><creatorcontrib>Antonelli, Francesca</creatorcontrib><creatorcontrib>Meletti, Stefano</creatorcontrib><creatorcontrib>Rispoli, Vittorio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Rauso, Giulia</au><au>Orlandi, Niccolò</au><au>Jacopetti, Marco</au><au>Bigliardi, Guido</au><au>Antonelli, Francesca</au><au>Meletti, Stefano</au><au>Rispoli, Vittorio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism</atitle><jtitle>Neurological sciences</jtitle><stitle>Neurol Sci</stitle><addtitle>Neurol Sci</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>45</volume><issue>7</issue><spage>3509</spage><epage>3511</epage><pages>3509-3511</pages><issn>1590-1874</issn><issn>1590-3478</issn><eissn>1590-3478</eissn><abstract>Background Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomatic treatments are required. Typical and atypical neuroleptics as well as tetrabenazine are considered therapies of choice. However, anecdotal reports of antiseizures medications and botulinum neurotoxin injection effectiveness have been described. Methods We described a case of severely disabling acute-onset lesional HB/HC, where high dosage of first- and second-line therapies was contraindicated due to patient’s comorbidities. Results After botulin neurotoxin (BoNT) injections in his left upper limb muscles (biceps brachii, triceps brachii, teres major, and deltoid), the patient experienced gradual reduction of hyperkinetic movements. The gradual discontinuation of topiramate (TPM) did not worsen the clinical picture. Discussion The reduction of hyperkinetic movements led to rhabdomyolysis resolution as well as cutaneous injuries healing with renal function improvement, so that the patient was able to be eligible for rehabilitation, which was prevented by HB/HC itself. The clinical improvement was consistent with BoNT pharmacokinetic. The administration of BoNT early after the onset of lesional HB/HC remarkably modified the clinical management and drove toward comorbidities resolution and rehabilitation. Conclusion The present case highlights the effectiveness of unconventional therapeutic options in disabling acute onset lesional HB/HC when first-line therapies are contraindicated. Particularly, this report may encourage BoNT application in the early stage of movement disorder emergencies.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38548894</pmid><doi>10.1007/s10072-024-07465-0</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-6728-8481</orcidid><orcidid>https://orcid.org/0000-0003-0334-539X</orcidid><orcidid>https://orcid.org/0000-0001-5312-7206</orcidid><orcidid>https://orcid.org/0000-0001-7159-9311</orcidid><orcidid>https://orcid.org/0000-0002-5717-7363</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1590-1874
ispartof Neurological sciences, 2024-07, Vol.45 (7), p.3509-3511
issn 1590-1874
1590-3478
1590-3478
language eng
recordid cdi_proquest_miscellaneous_3022567154
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Antipsychotics
Botulinum toxin
Botulinum Toxins, Type A - administration & dosage
Botulinum Toxins, Type A - therapeutic use
Brief Communication
Cerebrovascular diseases
Chorea - drug therapy
Comorbidity
Contraindications
Dyskinesias - drug therapy
Dyskinesias - etiology
Humans
Male
Medical treatment
Medicine
Medicine & Public Health
Middle Aged
Movement disorders
Muscles
Neurology
Neuromuscular Agents - administration & dosage
Neuromuscular Agents - therapeutic use
Neuroradiology
Neurosurgery
Patients
Pharmacokinetics
Psychiatry
Quality of life
Rehabilitation
Renal function
Rhabdomyolysis
Tetrabenazine
Topiramate
Vascular diseases
Wound healing
title Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A18%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Botulinum%20neurotoxin%20as%20early%20treatment%20in%20acute-onset%20lesional%20hemiballism&rft.jtitle=Neurological%20sciences&rft.au=Di%20Rauso,%20Giulia&rft.date=2024-07-01&rft.volume=45&rft.issue=7&rft.spage=3509&rft.epage=3511&rft.pages=3509-3511&rft.issn=1590-1874&rft.eissn=1590-3478&rft_id=info:doi/10.1007/s10072-024-07465-0&rft_dat=%3Cproquest_cross%3E3067592768%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3067592768&rft_id=info:pmid/38548894&rfr_iscdi=true